Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma

Similar documents
Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens. Low Grade Lymphoma

Myeloma. Alternative Schedule: Bortezomib 1.3 mg/m² SC days 1, 4, 8, 11. Q21 days

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Emetogenicity level 1. Emetogenicity level 2

General Authorization Criteria for ALL Agents and Indications:

Standard Regimens for Haematology

Pharmacy Prior Authorization Colony Stimulating Factor (CSF)/Myeloid Growth Factor (MGF) Clinical Guideline

Pharmacy Prior Authorization Colony Stimulating Factors Clinical Guideline. Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF)

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

CLINICAL MEDICAL POLICY

FULCVR Some parts of regimen

Disease Site Sub-Disease Site Intent Regimen Code Regimen Details Status (as of October 17, 2017) Breast Not Applicable Adjuvant / Curative

NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Peripheral T-Cell Lymphoma (Part 1 of 5)

Transitioning Inpatient Chemotherapy to the Outpatient Setting

療指引 Classical hodgkin lymphoma

Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.

See Important Reminder at the end of this policy for important regulatory and legal information.

MASCC Guidelines for Antiemetic control: An update

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

Guidelines for the Use of Anti-Emetics with Chemotherapy

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

Poteligeo (mogamulizmuab-kpkc)

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

Haematology, Oncology and Palliative Care Directorate.

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia

Lymphomas and multiple myeloma 12/23/2018 1

Inpatient Antineoplastic Medication Administration And Associated Drug Costs: Institution of a Hospital Policy Limiting Inpatient Administration

Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: Last Review Date: 11.18


Relapsed/Refractory Hodgkin Lymphoma

Gazyva (obinutuzumab)

Indium-111 Zevalin Imaging

ST-QBP: Systemic Treatment Quality-Based Program (formerly STFM) DF: Drug Formulary GYNECOLOGICAL SKIN HEMATOLOGY ST- QBP

LONG-TERM FOLLOW-UP OF TREATMENT OF BURKTT'S LYMPHOMA -SINGLE INSTITUTION EXPERIENCE

NCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12

ADULT Updated: September 4, 2018

CYTARABINE: Class: Antineoplastic Agent, Antimetabolite (Pyrimidine Analog)

R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement)

Change Summary - Form 2018 (R3) 1 of 12

DRUG EXTRAVASATION. Vesicants. Irritants

Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University

Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice

Non-Hodgkin s Lymphoma

Guideline Update on Antiemetics

Patient 1: Patient 2:

Clinical Tools and Resources for Self-Study and Patient Education

ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99)

LYIVAC (Magrath B) + R (rituximab) [To be used after LYCODOX-M (Magrath A) + R]

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders

The problem. The treatment. Special situations. Brief background on HBV Definitions of HBV reactivation. The role and timing of antiviral therapy

Chemotherapy dosing in pediatric patient. Surapon Wiangnon Suddhavej Hospital Faculty of Medicine Mahasarakham University

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data

Job title: Consultant Pharmacist/Advanced Practice Pharmacist

B Cell Lymphoma: Aggressive

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.

Clinical Policy: Pemetrexed (Alimta) Reference Number: CP.PHAR.368 Effective Date: Last Review Date: Line of Business: Medicaid

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY

Subject: Palonosetron Hydrochloride (Aloxi )

Disclosures WOJCIECH JURCZAK

Subtype Review. Lymphoma einformation Project (LeIP) Mantle Cell Lymphoma

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-IVE.DOC CONTROLLED DOC NO: HCCPG B53 CSIS Regimen Name: R-IVE. R-IVE Regimen

Supplementary appendix

ESCMID Online Lecture Library. by author

An introduction to the Essential Medicines concept: balancing innovation with public health priorities

X M/ (R) Dose adjusted (DA)-EPOCH-R

CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults

Clinical Management Guideline for Small Cell Lung Cancer

(R) CODOX M / (R) IVAC

For Health Professionals Who Care For Cancer Patients

CASE REPORT. Introduction

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

The treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona

Methylprednisolone iv to po dose

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

Pixantrone monotherapy for the treatment of relapsed or refractory aggressive non-hodgkin s lymphoma

Non-Hodgkin Lymphoma in Clinically Difficult Situations

ESCMID Online Lecture Library. by author

DRUG PROPERTIES YOU NEED TO KNOW

Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy

Changing the landscape of treatment in Peripheral T-cell Lymphoma

Lymphoma. Anas Younes, MD Professor of Medicine The University of Texas M. D. Anderson Cancer Center Houston, TX

Patterns of Chemotherapy Administration in Patients With Intermediate-Grade Non-Hodgkin s Lymphoma

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and

Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!

Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines

Essentials. Oncology Practise Essentials. Oncology Basics. Tutorial 2. Cancer Chemotherapy

Transcription:

Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for high grade and Burkitt s lymphoma used in the adjuvant/curative/neo-adjuvant setting. It is expected that the prescribing oncologist will select the regimen from the list of evidence-informed regimens that is most appropriate for their patient taking account of a variety of disease-specific and patient-related factors. Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent. Regimen Code BEACOPP Etoposide 200 mg/m² IV days 1-3; DOXOrubicin 35 mg/m² IV day 1; Cyclophosphamide 1250 mg/m² IV day 1; Procarbazine 100 mg/m² PO daily, days 1-7; Prednisone 40 mg/m² PO daily, days 1-14; Bleomycin 10 mg/m² IV day 8; vincristine 1.4 mg/m 2 (max 2 mg) IV day 8. CEOP Cyclophosphamide 750 mg/m² IV day 1; Etoposide 50 mg/m² IV day 1; Etoposide 100 mg/m² PO days 2-3; Vincristine 1.4 mg/m² (max 2 mg) IV day 1; Prednisone 100 mg PO daily on days 1-5. CEOP+RITU Cyclophosphamide 750 mg/m² IV day 1; Etoposide 50 mg/m² IV day 1; Etoposide 100 mg/m² PO days 2-3; Vincristine 1.4 mg/m² (max 2 mg) IV day 1; Prednisone 100 mg PO daily on days 1-5; CEPP(B) Cyclophosphamide 600-750mg/m² IV days 1, 8; Etoposide 70 mg/m² IV days 1, 2, 3; Procarbazine 60 mg/m² PO daily, days 1-10; Prednisone 60mg/m² PO daily, days 1-10; Bleomycin 15 units/m² IV days 1, 15. Alternative Etoposide schedule: 70 mg/m² IV day 1 and 140 mg/m² PO daily, days 2 and 3

Procarbazine may be dropped from the regimen CEPIOP Cyclophosphamide 750 mg/m² IV day 1; epirubicin 50mg/m² IV day 1; Prednisone 100 mg PO daily, days 1-5. CEPIOP+RITU Cyclophosphamide750 mg/m² IV day 1; epirubicin 50 mg/m² IV day 1; CEPP Cyclophosphamide 600-750 mg/m² IV days 1 and 8; Etoposide 70 mg/m² IV day 1; Etoposide 140 mg/m² PO days 2-3; Procarbazine 60 mg/m² PO daily, days 1-10; Prednisone 60 mg/m² PO daily, days 1-10. CEPP+RITU Cyclophosphamide 600-750 mg/m² IV days 1 and 8; Etoposide 70 mg/m² IV day 1; Etoposide 140 mg/m² PO day 2-3; Procarbazine 60 mg/m² PO daily, day 1-10; Prednisone 60 mg/m² PO daily, days 1-10; rituximab 375mg/m² IV day 1. CHOEP Cyclophosphamide 750 mg/m² IV day 1; Etoposide 100 mg/m² IV day 1; Etoposide 200 mg/m² PO days 2-3; Prednisone 100 mg PO daily, days 1-5. CHOEP+RITU Cyclophosphamide 750 mg/m² IV day 1; Etoposide 100 mg/m² IV day 1 ; Etoposide 200 mg/m² PO days 2-3;

Regimen Code CHOP Cyclophosphamide 750 mg/m² IV day 1; Prednisone 100 mg PO daily, days 1-5. CHOP+R Cyclophosphamide 750 mg/m² IV day 1; CHOP14+R Cyclophosphamide 750 mg/m² IV day 1; Q14 days CNOP Cyclophosphamide 750 mg/m² IV day 1; MitoXANTRONE 10 mg/m² IV day 1; Prednisone 50 mg/m²/day PO days 1-5. CYCLETOP Cyclophosphamide 2000 mg/m² IV day 1; Etoposide 200 mg/m² IV days 1-3. CYTAMTRX(IT) DHAP ESHAP EPOCH+RITU Schedule and frequency is variable, one option is: Methotrexate 12 mg + Cytarabine 40 mg IT +/- Hydrocortisone 15 mg IT 2 injections/week for 4 weeks CISplatin 100 mg/m² IV day 1; Cytarabine 2000 mg/m² IV over 2 hours Q12 hours x 2 doses, day 2; Dexamethasone 40 mg PO days 1-4. Etoposide 40 mg/m²/day IV days 1-4; CISplatin 25 mg/m²/day CIV days 1-4; Cytarabine 2000 mg/m² IV day 5 only; Methylprednisolone 500 mg IV days 1-5; rituximab 375 mg/m 2 IV day 1 (before starting EPOCH); Etoposide 50 mg/m 2 /day CIV days 1 to 4; vincristine 0.4 mg/m 2 /day CIV days 1 to 4; DOXOrubicin 10 mg/m 2 /day CIV days 1 to 4; Cyclophosphamide 750 mg/m 2 IV day 5; Prednisone 60 mg/m 2 PO daily or BID days 1 to 5

Note: this is dose-adjusted EPOCH GDP Gemcitabine 1000 mg/m² IV days 1,8; Dexamethasone 40 mg PO days 1-4; CISplatin 75 mg/m² IV day 1. HYPERCVAD Course A: Cyclophosphamide 600 mg/m² IV days 1-3 (max 1320 mg); DOXOrubicin 50 mg/m² IV day 4*; vincristine 1.4 mg/m² (max 2 mg) IV days 4* and 11; Dexamethasone 40 mg PO days 1, 2, 3, 4, 11, 12, 13, 14. *some centres may administer on day 3 HYPERCVAD+RITU Course B: Inpatient Course A: Cyclophosphamide 600 mg/m² IV days 1-3 (max 1320 mg); DOXOrubicin 50 mg/m² IV day 4*; vincristine 1.4 mg/m² (max 2 mg) IV days 4* and 11; Dexamethasone 40 mg PO days 1, 2, 3, 4, 11, 12, 13, 14; *some centres may administer on day 3 ICE Course B: Inpatient Mesna 1667 mg/m² IV days 1-3; Ifosfamide 1667 mg/m² IV days 1-3; Mesna 2000 mg PO days 1-3 (2 and 4 hours post-ifosfamide); CARBOplatin AUC 5 IV day 1; Etoposide 100 mg/m² IV days 1-3.

MINIBEAM MTRX(IT) Carmustine 60 mg/m² IV day 1; Etoposide 75 mg/m² IV days 2-5; Cytarabine 100 mg/m² IV Q12 hours, days 2-5; Melphalan 30 mg/m² IV day 6 (or may give 6 mg/m² IV daily for 5 days, or entire dose on day 5 for outpatient administration). Q28-42 days Methotrexate 12 mg IT Schedule and frequency depends on treatment intent and disease status (i.e. prophylactic or established CNS involvement) GDP+RITU Gemcitabine 1000 mg/m² IV days 1 and 8; Dexamethasone 40 mg PO days 1-4; CISplatin 75 mg/m² IV day 1; rituximab 375 mg/m² IV day 1 Not currently publicly funded for this regimen and intent RITU(IT) rituximab 25-40 mg IT once or twice weekly for up to 8 injections not currently publicly funded for this regimen and intent

CODOXM Burkitt s Lymphoma : cyclophosphamide 800 mg/m² IV day 1; DOXOrubicin 40 mg/m² IV day 1; vincristine 1.5 mg/m² (max 2 mg) IV days 1, 8 (also day 15 in cycle 3); Cytarabine 70mg IT days 1, 3; cyclophosphamide 200 mg/m² IV days 2-5; Inpatient Methotrexate 1200 mg/m² IV day 10; Inpatient Methotrexate 240 mg/m² /hour x 23 hours, CIV day 10; Inpatient Leucovorin 192 mg/m² IV 12 hours post-methotrexate day 11; Inpatient Leucovorin 12 mg/m² IV Q6 hours until Methotrexate clear. CODOXM+RITU : Cyclophosphamide 800 mg/m² IV day 1; DOXOrubicin 40 mg/m² IV day 1; vincristine 1.5 mg/m² (max 2 mg) IV days 1 and 8 (also day 15 in cycle 3); Cytarabine 70 mg IT days 1 and 3; rituximab 375 mg/m² IV day 1*; Cyclophosphamide 200 mg/m² IV days 2-5; Inpatient Methotrexate 1200 mg/m² IV day 10; Inpatient Methotrexate 240 mg/m² /hour x 23 hours, CIV day 10; Inpatient Leucovorin 192 mg/m² IV 12 hours post-methotrexate day 11; Inpatient Leucovorin 12 mg/m² IV Q6 hours until Methotrexate clear. EPOCH+RITU *dose may be postponed to later in the cycle if clinically indicated rituximab 375 mg/m 2 IV day 1 (before starting EPOCH); Etoposide 50 mg/m 2 /day CIV days 1 to 4; vincristine 0.4 mg/m 2 /day CIV days 1 to 4; DOXOrubicin 10 mg/m 2 /day CIV days 1 to 4; Cyclophosphamide 750 mg/m 2 IV day 5; Prednisone 60 mg/m 2 PO daily or BID days 1 to 5 Note: this is dose-adjusted EPOCH Last Updated: February 2017